Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. Specifically, the stock is overvalued on EV/EBITDA.
Target Price
The average target price of SVRA is 11 and suggests 93% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell